It is also worth noting that while concurrent CD79B and MYD88 mutations appear to sensitize systemic lymphoma to ibrutinib [62], this same combination was associated with a poorer response in CNS disease, perhaps due to decreased dependence on the BCR pathway [55]. This evidence concerns the gene CD79B and lymphoma.